Drug Profile


Alternative Names: LATIN T1D; NN 2211; NN 9211; NN-8022; NNC 90-1170; Saxenda; Victoza

Latest Information Update: 24 Jun 2017

Price : $50

At a glance

  • Originator Novo Nordisk
  • Developer Cedars-Sinai Medical Center; Hvidovre Hospital; Novo Nordisk
  • Class Antihyperglycaemics; Glucagon-like peptides; Obesity therapies
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Obesity; Type 2 diabetes mellitus
  • Phase II Parkinson's disease
  • Discontinued Type 1 diabetes mellitus

Most Recent Events

  • 22 Jun 2017 The CHMP of the EMA recommends approval for label extension for liraglutide to include long-term data from the phase III LEADER trial
  • 27 Apr 2017 The US FDA approves liraglutide label update to include long-term data from the phase IIIa SCALE™ trial
  • 27 Apr 2017 Updated long-term efficacy data from the phase IIIa SCALE™ trial in Obesity released by Novo Nordisk
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top